The Quantellect read.As of Nov 19, 2026, 3 active firms cover Nutex Health Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $306.00 to $325.00, so the covering firms are broadly aligned. The average target of $313.67 sits 82% above the current $171.95. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 2 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $7.09 next quarter toward $27.95 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$313.67
+82.4% upside
Average target across 3 active firms as of Nov 19, 2026 vs $171.95 current
Highest Target$325.00
Average Target$313.67
Lowest Target$306.00
Detailed analyst forecasts for NUTX
Showing 1–4 of 4 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate NUTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NUTX EPS & revenue forecast
EPS · NEXT QUARTER
$7.09
Range $5.95 – $7.81 · 6 analysts · +9% YoY
Next period, 6 analysts expect Nutex Health Inc to earn $7.09 a share (range $5.95 – $7.81), versus $6.52 a year earlier. Full-year consensus is $27.45, growing to $27.95 the year after.
REVENUE · NEXT QUARTER
$234.9M
Range $232.1M – $241.1M · 6 analysts · +9% YoY
Revenue is expected to reach $234.9M (range $232.1M – $241.1M), +8.5% year-over-year. Full-year consensus is $871.1M, rising to $964.8M next year.
Top analysts covering Nutex Health Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NUTX.
#1
BS
Bill Sutherland
Benchmark · Rank #48
Buy
$300.00+74.5% to target
Overall win rate
46%
+ Follow
#2
Anthony Vendetti
Maxim Group · Rank #456
Buy
$200.00+16.3% to target
Overall win rate
28%
+ Follow
#3
BH
Ben Haynor
Lake Street
Buy
$310.00+80.3% to target
Coverage
—
+ Follow
#4
GM
Gene Mannheimer
Freedom Capital Markets
Buy
$306.00+78.0% to target
Coverage
—
+ Follow
#5
EM
Eugene Mannheimer
Freedom Capital Markets
Buy
$306.00+78.0% to target
Coverage
—
+ Follow
NUTX stock forecast FAQ
What is NUTX's average 12-month price target?+
The 3 active firms with a live target average $313.67 for Nutex Health Inc over the next 12 months, ranging from a $325.00 high to a $306.00 low, as of Nov 19, 2026.
Is NUTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NUTX?+
The Street-high target is $325.00 (B. Riley Securities), and the Street-low is $306.00 (Freedom Capital Markets). The average of all 3 active-firm targets is $313.67.
How many active Wall Street firms cover NUTX?+
3 active firms have a recognized rating on Nutex Health Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NUTX?+
Among analysts who currently cover NUTX, Bill Sutherland of Benchmark has the strongest overall Quantellect track record (Rank #48). Their current call is Buy with a $300.00 target.
What is Nutex Health Inc's projected EPS for next quarter?+
The consensus estimate is $7.09 per share (range $5.95 – $7.81) across 6 analysts. Full-year EPS is projected at $27.45, rising to $27.95 the following year.
How much revenue is Nutex Health Inc expected to report next quarter?+
Consensus revenue is $234.9M (range $232.1M – $241.1M). Full-year revenue is projected at $871.1M, growing to $964.8M next year.
Have analysts been upgrading or downgrading NUTX lately?+
As of Nov 19, 2026, 3 of 3 active firms rate NUTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NUTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.